梗阻性肥厚型心肌病的双异丙吡胺治疗入门。
A primer of disopyramide treatment of obstructive hypertrophic cardiomyopathy.
机构信息
Division of Cardiology, St. Luke's-Roosevelt Hospital Center, New York, NY 10019, USA.
出版信息
Prog Cardiovasc Dis. 2012 May-Jun;54(6):483-92. doi: 10.1016/j.pcad.2012.04.003.
PMID:22687589
Abstract
Hypertrophic cardiomyopathy (HCM) occurs in 1 in 500 individuals. Treatment options for HCM differ from those administered in coronary disease, heart failure, and valvular disease patients that comprise the core of many cardiology practices. In this article, we offer a concise summary of the therapeutic use of disopyramide for reducing gradients and relieving symptoms in obstructive HCM.
摘要
肥厚型心肌病（HCM）在每 500 人中就有 1 人患病。HCM 的治疗选择与冠心病、心力衰竭和瓣膜性心脏病患者的治疗选择不同，后者构成了许多心脏病学实践的核心。在本文中，我们简要总结了双异丙吡胺在降低梗阻性 HCM 梯度和缓解症状方面的治疗用途。
Zotero 插件